Outstanding Recoveries

• Home
• Outstanding Recoveries

Verdicts & Settlements

• 

  $118+ Million Settlement – Disposable Contact Lens Antitrust Litigation

  In re Disposable Contact Lens Antitrust Litigation, 3:15-md-02626 (U.S. District Court for the Middle District of Florida)

  See More

  Milberg represented indirect purchasers in a class action alleging that defendants conspired to maintain artificially high prices for disposable contact lenses through policies that prevented resale of the subject contact lenses below a minimum price. Settlements exceeded $118 million.
• 

  $2.4 Billion Settlement – ACTOS Antitrust Litigation

  In re Actos End Payor Antitrust Litigation, Case No. 1:13-cv-09244 (U.S. District Court for the Southern District of New York)

  See More

  Milberg attorneys played a significant role in this litigation, including appointment to the MDL Discovery Committee, which accused Takeda Pharmaceuticals of failing to warn patients of the risks of bladder cancer, heart failure and other side effects associated with the Type 2 diabetes drug. In 2015, roughly 9,000 claims were settled for $2.4 billion and significant injunctive relief.
• 

  $750 Million Settlement – Carlson v. Xerox Corp

  In re Carlson v. Xerox Corp., No. 00-1621 (D. Conn.)

  See More

  Milberg served as plaintiffs’ Co-Lead Counsel in these consolidated cases alleging that Xerox and several officers violated the federal securities laws by issuing false financial statements. The plaintiffs’ claims survived three motions to dismiss and a motion for summary judgment, ultimately resulting in a $750 million settlement in 2009.
• 

  $138 Million Settlement – Biovail Corp. Securities Litigation

  In re Biovail Corp. Securities Litigation, No. 03-8917 (S.D.N.Y.)

  See More

  Milberg, representing Local 282 Welfare Trust Fund and serving as Co-Lead Counsel, litigated this securities action alleging that defendants made misleading statements concerning Biovail’s financial results and its drug, Cardizem LA. Following substantial discovery, including depositions across the U.S. and Canada, Milberg obtained a $138 million settlement for the class, and Biovail agreed to institute significant corporate governance changes.
• 

  $100 Million Settlement – General Electric Co. ERISA Litigation

  In re General Electric Co. ERISA Litigation, No. 04-1398 (N.D.N.Y.)

  See More

  Milberg, serving as Co-Lead Counsel, achieved a $40 million settlement on behalf of current and former G.E. employees who claimed that G.E.’s 401(k) Plan fiduciaries imprudently invested more than two-thirds of the Plan’s assets in company stock. The settlement included important structural changes to G.E.’s 401(k) plan valued at more than $100 million.